check_circleStudy Completed
Prostatic Neoplasms, Castration-Resistant
Bayer Identifier:
18530
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Healthcare costs of mCRPC in university hospitals in Japan
Trial purpose
The study was a local, retrospective, observational, single-cohort study based on secondary data and was conducted to determine the healthcare costs in metastatic castration resistant prostate cancer (mCRPC) in national university hospitals in Japan.
Key Participants Requirements
Sex
MaleAge
20 - N/ATrial summary
Enrollment Goal
4001Trial Dates
December 2015 - May 2016Phase
Phase 4Could I Receive a placebo
N/AProducts
UnspecifiedAccepts Healthy Volunteer
NoPrimary Outcome
- Mean and median medical costs per month for mCRPC patients, including the breakdown of the medical costsdate_rangeTime Frame:Up to 1 year
- Healthcare resource use (hospital ward/ intensive care unit/ inpatient visit) per year as a consequence of mCRPC diagnosisdate_rangeTime Frame:Up to 1 year
- Diagnostic patterns before and after mCRPC diagnosisIncludes imaging or laboratory examinationsdate_rangeTime Frame:Up to 1 year
- Skeletal related events (SREs) frequency, rate, and treatment patterns.date_rangeTime Frame:Up to 1 year
Secondary Outcome
- Correlation between frequency of skeletal related events and medical costs per monthdate_rangeTime Frame:Up to 1 year
- Correlation between frequency of skeletal related events and medication typedate_rangeTime Frame:Up to 1 year
- Correlation between patient disease status and treatment patternsdate_rangeTime Frame:Up to 1 year
- Correlation between patient disease status and medical costs per monthdate_rangeTime Frame:Up to 1 year
Trial design
Trial Type
ObservationalIntervention Type
N/ATrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A